Truveta wants to give healthcare researchers something that has long eluded them: the ability to ask a question about real-world patient data and get an answer in minutes, not months.
The Bellevue, Wash.-based health data company on Tuesday announced Truveta Intelligence, a new AI-powered tool that lets researchers and healthcare leaders ask natural language questions about patient populations, treatments, and outcomes.
The answers from the tool are drawn from continuously updated, de-identified clinical records covering more than 130 million patients. Truveta has access to the data through its network of 30 health system partners, representing more than 18% of daily clinical care in the U.S.
The key distinction from other AI tools in healthcare, the company says, is that Truveta Intelligence isn’t summarizing published research. Instead, it’s querying live clinical data.
The tool could give drug makers faster insight into how new therapies are performing, help health systems spot variation in patient outcomes, and let public health researchers detect emerging trends earlier based on information that is much closer to real-time.
Truveta was founded in 2020 with roots at Providence, the large health system based in Washington state. Terry Myerson, a former Microsoft executive vice president who led the company’s Windows and Devices Group, has led the company as CEO since its inception.
The company raised $320 million in January 2025 in a round involving Regeneron, Illumina, and 17 health systems, pushing its valuation above $1 billion. The company, ranked No. 3 on the GeekWire 200, has raised $515 million to date and has more than 400 employees.
Truveta Intelligence is available now to existing Truveta Data subscribers, which include life sciences companies and health systems.
